ArticleESMO open2026

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

M Cruellas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.